LY3202626 + itraconazole

LY3202626 + itraconazole refers to the co-administration of LY3202626, an investigational oral small molecule inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), and itraconazole, an established oral antifungal agent and potent inhibitor of cytochrome P450 3A4 (CYP3A4). LY3202626 was developed by Eli Lilly for the treatment of Alzheimer’s disease, to reduce beta-amyloid production by inhibiting BACE1, but its development has been discontinued after Phase 2 failure due to lack of efficacy and safety concerns[1][3][5]. Itraconazole was used in early phase clinical studies to evaluate pharmacokinetic interactions, owing to its strong effect on drug metabolism[2][4]. This combination does not represent an approved fixed-dose or uniquely branded pharmaceutical product; it was used in research settings to assess the effect of strong CYP3A4 inhibition on LY3202626 metabolism.